NATIONAL INSTITUTES OF HEALTH
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
NCI COVID-19 in Cancer Patients, NCCAPS Study
- Conditions
- Metastatic Malignant Solid NeoplasmCOVID-19 InfectionHematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm
- Interventions
- Procedure: Biospecimen CollectionOther: Data CollectionOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1877
- Registration Number
- NCT04387656
- Locations
- πΊπΈ
Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, United States
πΊπΈBlank Children's Hospital, Des Moines, Iowa, United States
πΊπΈDayton Physicians LLC-Wayne, Greenville, Ohio, United States
Testing the Safety of CB-5339 in Patients With Cancer
- Conditions
- Aggressive Non-Hodgkin LymphomaIndolent Non-Hodgkin LymphomaLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
- Interventions
- Drug: p97 Inhibitor CB-5339 Tosylate
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04372641
- Locations
- πΊπΈ
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
πΊπΈNational Institutes of Health Clinical Center, Bethesda, Maryland, United States
Tocilizumab for Patients With Cancer and COVID-19 Disease
- Conditions
- Malignant Solid NeoplasmPneumoniaPneumonitisSevere Acute Respiratory Distress SyndromeHematopoietic and Lymphoid Cell NeoplasmSymptomatic COVID-19 Infection Laboratory-Confirmed
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT04370834
- Locations
- πΊπΈ
Valley Medical Center, Renton, Washington, United States
πΊπΈUniversity Medical Center of Southern Nevada, Las Vegas, Nevada, United States
πΊπΈNational Cancer Institute, Rockville, Maryland, United States
The Modification of Diet in Renal Disease Study
- Conditions
- Chronic Renal Disease
- Interventions
- Other: Low Protein DietOther: Usual Protein DietOther: Very Low Protein DietDrug: Medications needed to maintain low blood pressureDrug: Medications needed to maintain usual blood pressure
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2020-04-27
- Target Recruit Count
- 840
- Registration Number
- NCT04364113
African American Study of Kidney Disease and Hypertension
- Conditions
- Hypertensive NephrosclerosisChronic Renal Insufficiency
- Interventions
- Other: MAP goal less than or equal to 92 mm HgOther: MAP goal 102-107 mm Hg
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2020-04-27
- Target Recruit Count
- 1094
- Registration Number
- NCT04364139
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
- Conditions
- COVID-19
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 679
- Registration Number
- NCT04362865
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
πΊπΈMedstar Montgomery Medical Center, Olney, Maryland, United States
πΊπΈMedstar Washington Hospital Center, Washington, District of Columbia, United States
Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
- Conditions
- Adrenocortical Carcinoma
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1000
- Registration Number
- NCT04358107
- Locations
- πΊπΈ
National Cancer Institute (NCI), Bethesda, Maryland, United States
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaUnresectable Triple-Negative Breast Carcinoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT04345913
- Locations
- πΊπΈ
Smilow Cancer Hospital Care Center at Long Ridge, Stamford, Connecticut, United States
πΊπΈMemorial Hospital East, Shiloh, Illinois, United States
πΊπΈUniversity of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
- Conditions
- Metastatic Primary Central ChondrosarcomaLocally Advanced Unresectable Primary Central ChondrosarcomaUnresectable Primary Central Chondrosarcoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT04340843
- Locations
- πΊπΈ
Salina Regional Health Center, Salina, Kansas, United States
πΊπΈUniversity of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States
πΊπΈMayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
- Conditions
- Autoimmune LymphoproliferativeCommon Variable ImmunodeficiencyImmune System DiseasesPrimary T-cell Immunodeficiency DisordersLymphoproliferative Disorders
- Interventions
- Radiation: Total body IrradiationProcedure: Allogeneic HSCT
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT04339777
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States